NCT03995147View on ClinicalTrials.gov

Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

August 29, 2019

Primary Completion Date

February 20, 2027

Study Completion Date

February 20, 2027

Conditions
B Cell LymphomaLymphomaLymphoma, B-CellDiffuse Large B Cell LymphomaHigh-grade B-cell Lymphoma
Interventions
DRUG

Pembrolizumab

"Pembrolizumab will be administered at a fixed dose of 200mg intravenously every 3 weeks in combination with R-CHOP for 6 cycles.~Participants that respond to the combination regiment will continue to receive pembrolizumab 200 mg IV every 3 weeks for additional 35 cycles (2 years)."

DRUG

R-CHOP Protocol

R-CHOP chemo-immunotherapy will be administered in combination with Pembrolizumab

Trial Locations (1)

60637

The University of Chicago, Chicago

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Chicago

OTHER

NCT03995147 - Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma | Biotech Hunter | Biotech Hunter